146 related articles for article (PubMed ID: 34490624)
1. The cumulative incidence of cisplatin-induced hearing loss in young children is higher and develops at an early stage during therapy compared with older children based on 2052 audiological assessments.
Meijer AJM; Li KH; Brooks B; Clemens E; Ross CJ; Rassekh SR; Hoetink AE; van Grotel M; van den Heuvel-Eibrink MM; Carleton BC
Cancer; 2022 Jan; 128(1):169-179. PubMed ID: 34490624
[TBL] [Abstract][Full Text] [Related]
2. Prevalence and risk factors for cisplatin-induced hearing loss in children, adolescents, and young adults: a multi-institutional North American cohort study.
Moke DJ; Luo C; Millstein J; Knight KR; Rassekh SR; Brooks B; Ross CJD; Wright M; Mena V; Rushing T; Esbenshade AJ; Carleton BC; Orgel E
Lancet Child Adolesc Health; 2021 Apr; 5(4):274-283. PubMed ID: 33581749
[TBL] [Abstract][Full Text] [Related]
3. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2019 May; 5(5):CD009219. PubMed ID: 31063591
[TBL] [Abstract][Full Text] [Related]
4. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2014 Jul; (7):CD009219. PubMed ID: 24984156
[TBL] [Abstract][Full Text] [Related]
5. Hearing loss in Mexican children treated with cisplatin.
Castelán-Martínez OD; Jiménez-Méndez R; Rodríguez-Islas F; Fierro-Evans M; Vázquez-Gómez BE; Medina-Sansón A; Clark P; Carleton B; Ross C; Hildebrand C; Castañeda-Hernández G; Rivas-Ruiz R
Int J Pediatr Otorhinolaryngol; 2014 Sep; 78(9):1456-60. PubMed ID: 25037447
[TBL] [Abstract][Full Text] [Related]
6. Ototoxicity and long-term hearing outcome in pediatric patients receiving cisplatin.
Sriyapai T; Thongyai K; Phuakpet K; Vathana N; Buaboonnam J; Sanpakit K
Turk J Pediatr; 2022; 64(3):531-541. PubMed ID: 35899566
[TBL] [Abstract][Full Text] [Related]
7. Ototoxicity in children treated for osteosarcoma.
Lewis MJ; DuBois SG; Fligor B; Li X; Goorin A; Grier HE
Pediatr Blood Cancer; 2009 Mar; 52(3):387-91. PubMed ID: 19061216
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for cisplatin-associated ototoxicity in pediatric oncology patients.
Yancey A; Harris MS; Egbelakin A; Gilbert J; Pisoni DB; Renbarger J
Pediatr Blood Cancer; 2012 Jul; 59(1):144-8. PubMed ID: 22431292
[TBL] [Abstract][Full Text] [Related]
9. Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial.
Freyer DR; Chen L; Krailo MD; Knight K; Villaluna D; Bliss B; Pollock BH; Ramdas J; Lange B; Van Hoff D; VanSoelen ML; Wiernikowski J; Neuwelt EA; Sung L
Lancet Oncol; 2017 Jan; 18(1):63-74. PubMed ID: 27914822
[TBL] [Abstract][Full Text] [Related]
10. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2012 May; (5):CD009219. PubMed ID: 22592737
[TBL] [Abstract][Full Text] [Related]
11. Intravenous N-Acetylcysteine to Prevent Cisplatin-Induced Hearing Loss in Children: A Nonrandomized Controlled Phase I Trial.
Orgel E; Knight KR; Chi YY; Malvar J; Rushing T; Mena V; Eisenberg LS; Rassekh SR; Ross CJD; Scott EN; Neely M; Neuwelt EA; Muldoon LL; Freyer DR
Clin Cancer Res; 2023 Jul; 29(13):2410-2418. PubMed ID: 37134194
[TBL] [Abstract][Full Text] [Related]
12. Determinants of ototoxicity in 451 platinum-treated Dutch survivors of childhood cancer: A DCOG late-effects study.
Clemens E; de Vries AC; Pluijm SF; Am Zehnhoff-Dinnesen A; Tissing WJ; Loonen JJ; van Dulmen-den Broeder E; Bresters D; Versluys B; Kremer LC; van der Pal HJ; van Grotel M; van den Heuvel-Eibrink MM;
Eur J Cancer; 2016 Dec; 69():77-85. PubMed ID: 27821322
[TBL] [Abstract][Full Text] [Related]
13. Concordance between the chang and the International Society of Pediatric Oncology (SIOP) ototoxicity grading scales in patients treated with cisplatin for medulloblastoma.
Bass JK; Huang J; Onar-Thomas A; Chang KW; Bhagat SP; Chintagumpala M; Bartels U; Gururangan S; Hassall T; Heath JA; McCowage G; Cohn RJ; Fisher MJ; Robinson G; Broniscer A; Gajjar A; Gurney JG
Pediatr Blood Cancer; 2014 Apr; 61(4):601-5. PubMed ID: 24504791
[TBL] [Abstract][Full Text] [Related]
14. Hearing loss after platinum treatment is irreversible in noncranial irradiated childhood cancer survivors.
Clemens E; de Vries AC; Am Zehnhoff-Dinnesen A; Tissing WJ; Loonen JJ; Pluijm SF; van Dulmen-den Broeder E; Bresters D; Versluys B; Kremer LC; van der Pal HJ; Neggers SJ; van Grotel M; M van den Heuvel-Eibrink M
Pediatr Hematol Oncol; 2017 Mar; 34(2):120-129. PubMed ID: 28590156
[TBL] [Abstract][Full Text] [Related]
15. Transtympanic Sodium Thiosulfate for Prevention of Cisplatin-Induced Ototoxicity: A Randomized Clinical Trial.
Duinkerken CW; de Weger VA; Dreschler WA; van der Molen L; Pluim D; Rosing H; Nuijen B; Hauptmann M; Beijnen JH; Balm AJM; de Boer JP; Burgers JA; Marchetti S; Schellens JHM; Zuur CL
Otol Neurotol; 2021 Jun; 42(5):678-685. PubMed ID: 33710154
[TBL] [Abstract][Full Text] [Related]
16. Different infusion durations for preventing platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2016 Aug; (8):CD010885. PubMed ID: 27498707
[TBL] [Abstract][Full Text] [Related]
17. Role of Cisplatin Dose Intensity and TPMT Variation in the Development of Hearing Loss in Children.
Siemens A; Brooks B; Rassekh SR; Meijer AJM; van den Heuvel-Eibrink MM; Xu W; Loucks CM; Ross CJD; Carleton BC;
Ther Drug Monit; 2023 Jun; 45(3):345-353. PubMed ID: 36917731
[TBL] [Abstract][Full Text] [Related]
18. Cisplatin-induced hearing loss: the need for a long-term evaluating system.
Yasui N; Adachi N; Kato M; Koh K; Asanuma S; Sakata H; Hanada R
J Pediatr Hematol Oncol; 2014 May; 36(4):e241-5. PubMed ID: 24072246
[TBL] [Abstract][Full Text] [Related]
19. Development and validation of a cisplatin dose-ototoxicity model.
Dille MF; Wilmington D; McMillan GP; Helt W; Fausti SA; Konrad-Martin D
J Am Acad Audiol; 2012; 23(7):510-21. PubMed ID: 22992258
[TBL] [Abstract][Full Text] [Related]
20. Different infusion durations for preventing platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD010885. PubMed ID: 31961948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
